Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing

(1) Background: Leclercia adecarboxylata (L. adecarboxylata) is a gram-negative bacillus of the Enterobacteriaceae family, which is uncommonly isolated from clinical specimens. L. adecarboxylata is considered as an aquatic opportunistic pathog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Souheil Zayet, Stephane Lang, Pauline Garnier, Alix Pierron, Julie Plantin, Lynda Toko, Pierre-Yves Royer, Marc Villemain, Timothée Klopfenstein, Vincent Gendrin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	<i>Leclercia adecarboxylata</i> emerging pathogen MALDI-TOF clinical features antimicrobial susceptibility Medicine R
Acceso en línea:	https://doaj.org/article/3394b0225f484f1aa63c23c2c060ad71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3394b0225f484f1aa63c23c2c060ad71
record_format	dspace
spelling	oai:doaj.org-article:3394b0225f484f1aa63c23c2c060ad712021-11-25T18:37:55Z<i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing10.3390/pathogens101113992076-0817https://doaj.org/article/3394b0225f484f1aa63c23c2c060ad712021-10-01T00:00:00Zhttps://www.mdpi.com/2076-0817/10/11/1399https://doaj.org/toc/2076-0817(1) Background: <i>Leclercia adecarboxylata</i> (<i>L. adecarboxylata</i>) is a gram-negative bacillus of the Enterobacteriaceae family, which is uncommonly isolated from clinical specimens. <i>L. adecarboxylata</i> is considered as an aquatic opportunistic pathogen and most of the human infections are polymicrobial and usually occur in immunocompromised hosts. (2) Methods: In this retrospective study, we included all <i>L. adecarboxylata</i> strains since the introduction of MALDI-TOF MS in the Microbiology Department of <i>Nord Franche-Comté</i> Hospital, France (from 1 March 2015 to 31 July 2019). We studied demographic characteristics, comorbidities, characteristics of the current infection and outcome as well as antimicrobial susceptibility testing in all isolates. (3) Results: A total of 8 samples were identified (in 6 patients (4M/2F), with a recurrent <i>L. adecarboxylata</i> infection in 2 patients). The patients’ mean age was 66.2 years (range: 19–84). All patients were considered as immunocompetent, except a peritoneal dialysis patient with kidney transplantation. An exposition to an aquatic environment was identified in one patient. The most prevalent clinical feature was catheter-associated male urinary tract infection (in 3 cases) followed by ventilator-associated pneumonia (in 2 cases). One of 6 patients presented <i>L. adecarboxylata</i> bacteremia. <i>L. adecarboxylata</i> was part of a polymicrobial infection in 4 patients. The isolates showed a high susceptibility to all tested antibiotics, except one strain, which was resistant to fosfomycin. All patients with <i>L. adecarboxylata</i> infection were treated with antibiotics with a favorable outcome. (4) Conclusion: This study confirms the pathogenicity of <i>L. adecarboxylata</i>, even in immunocompetent patients, with a high susceptibility to antibiotics.Souheil ZayetStephane LangPauline GarnierAlix PierronJulie PlantinLynda TokoPierre-Yves RoyerMarc VillemainTimothée KlopfensteinVincent GendrinMDPI AGarticle<i>Leclercia adecarboxylata</i>emerging pathogenMALDI-TOFclinical featuresantimicrobial susceptibilityMedicineRENPathogens, Vol 10, Iss 1399, p 1399 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	<i>Leclercia adecarboxylata</i> emerging pathogen MALDI-TOF clinical features antimicrobial susceptibility Medicine R
spellingShingle	<i>Leclercia adecarboxylata</i> emerging pathogen MALDI-TOF clinical features antimicrobial susceptibility Medicine R Souheil Zayet Stephane Lang Pauline Garnier Alix Pierron Julie Plantin Lynda Toko Pierre-Yves Royer Marc Villemain Timothée Klopfenstein Vincent Gendrin <i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
description	(1) Background: <i>Leclercia adecarboxylata</i> (<i>L. adecarboxylata</i>) is a gram-negative bacillus of the Enterobacteriaceae family, which is uncommonly isolated from clinical specimens. <i>L. adecarboxylata</i> is considered as an aquatic opportunistic pathogen and most of the human infections are polymicrobial and usually occur in immunocompromised hosts. (2) Methods: In this retrospective study, we included all <i>L. adecarboxylata</i> strains since the introduction of MALDI-TOF MS in the Microbiology Department of <i>Nord Franche-Comté</i> Hospital, France (from 1 March 2015 to 31 July 2019). We studied demographic characteristics, comorbidities, characteristics of the current infection and outcome as well as antimicrobial susceptibility testing in all isolates. (3) Results: A total of 8 samples were identified (in 6 patients (4M/2F), with a recurrent <i>L. adecarboxylata</i> infection in 2 patients). The patients’ mean age was 66.2 years (range: 19–84). All patients were considered as immunocompetent, except a peritoneal dialysis patient with kidney transplantation. An exposition to an aquatic environment was identified in one patient. The most prevalent clinical feature was catheter-associated male urinary tract infection (in 3 cases) followed by ventilator-associated pneumonia (in 2 cases). One of 6 patients presented <i>L. adecarboxylata</i> bacteremia. <i>L. adecarboxylata</i> was part of a polymicrobial infection in 4 patients. The isolates showed a high susceptibility to all tested antibiotics, except one strain, which was resistant to fosfomycin. All patients with <i>L. adecarboxylata</i> infection were treated with antibiotics with a favorable outcome. (4) Conclusion: This study confirms the pathogenicity of <i>L. adecarboxylata</i>, even in immunocompetent patients, with a high susceptibility to antibiotics.
format	article
author	Souheil Zayet Stephane Lang Pauline Garnier Alix Pierron Julie Plantin Lynda Toko Pierre-Yves Royer Marc Villemain Timothée Klopfenstein Vincent Gendrin
author_facet	Souheil Zayet Stephane Lang Pauline Garnier Alix Pierron Julie Plantin Lynda Toko Pierre-Yves Royer Marc Villemain Timothée Klopfenstein Vincent Gendrin
author_sort	Souheil Zayet
title	<i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_short	<i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_full	<i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_fullStr	<i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_full_unstemmed	<i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing
title_sort	<i>leclercia adecarboxylata</i> as emerging pathogen in human infections: clinical features and antimicrobial susceptibility testing
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/3394b0225f484f1aa63c23c2c060ad71
work_keys_str_mv	AT souheilzayet ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT stephanelang ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT paulinegarnier ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT alixpierron ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT julieplantin ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT lyndatoko ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT pierreyvesroyer ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT marcvillemain ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT timotheeklopfenstein ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting AT vincentgendrin ileclerciaadecarboxylataiasemergingpathogeninhumaninfectionsclinicalfeaturesandantimicrobialsusceptibilitytesting
_version_	1718410884655611904

<i>Leclercia adecarboxylata</i> as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing

Ejemplares similares